ProductResearchPreclinicalPhase 1Phase 2Phase 3
GI Immunology & Inflammation
AMT-101
ORAL IL-10

ULCERATIVE COLITIS - combination with anti-TNFα

AMT-101
ORAL IL-10

POUCHITIS

AMT-101
ORAL IL-10

ULCERATIVE COLITIS - biologic naïve and experienced monotherapy

AMT-101
ORAL IL-10

RHEUMATOID ARTHRITIS - combination with anti-TNFα

AMT-126
ORAL IL-22

GI BARRIER REPAIR

Metabolism
ORAL hGH

HORMONE DEFICIENCY

GI
ORAL GLP-2

INTESTINAL REHAB

Research
Multiple Projects

MULTIPLE INDICATIONS

GI Immunology & Inflammation
AMT-101
ORAL IL-10
ULCERATIVE COLITIS - combination with anti-TNFα
Phase 2
AMT-101
ORAL IL-10
POUCHITIS
Phase 2
AMT-101
ORAL IL-10
ULCERATIVE COLITIS - biologic naïve and experienced monotherapy
Phase 2
AMT-101
ORAL IL-10
RHEUMATOID ARTHRITIS - combination with anti-TNFα
Phase 2
AMT-126
ORAL IL-22
GI BARRIER REPAIR
Phase 1
Metabolism
ORAL hGH
HORMONE DEFICIENCY
Preclinical
GI
ORAL GLP-2
INTESTINAL REHAB
Preclinical
Research
Multiple Projects
MULTIPLE INDICATIONS
Preclinical

AMT maintains worldwide rights to all product candidates and research programs.

By initially developing medicines for known and validated targets, we remove de novo target risk and focus on optimizing each product for patients. Each AMT product is designed for maximal efficacy with improved safety, in a patient-friendly oral format.